Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on‐demand treatment of hereditary angioedema

BACKGROUND: Hereditary angioedema (HAE) is a rare genetic disease that leads to recurrent episodes of swelling and pain caused by uncontrolled plasma kallikrein (PKa) activity. Current guidelines recommend ready availability of on‐demand HAE treatments that can be administered early upon attack onse...

Descripción completa

Detalles Bibliográficos
Autores principales: Duckworth, Edward J., Murugesan, Nivetha, Li, Lily, Rushbrooke, Louise J., Lee, Daniel K., De Donatis, Gian Marco, Maetzel, Andreas, Yea, Christopher M., Hampton, Sally L., Feener, Edward P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544254/
https://www.ncbi.nlm.nih.gov/pubmed/35278245
http://dx.doi.org/10.1111/cea.14122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544254/
https://www.ncbi.nlm.nih.gov/pubmed/35278245
http://dx.doi.org/10.1111/cea.14122

Ejemplares similares